$AstraZeneca (AZN.US)$
Can This Breakthrough Breast Cancer Drug Transform AstraZeneca's Oncology Portfolio?

$LumiraDx (LMDXF.US)$ if we started bringing awareness to X FB and other social media platforms we could probably win this fight. I stayed in Lumiradx because I figured if $AstraZeneca (AZN.US)$ had scooped it up we would have been jipped. $ROCHE HOLDING AG (RHHBY.US)$ seemed like a better fit as they have a plethora of innovative solutions to revitalize companies. 350m seems like an $Abbott Laboratories (ABT.US)$ or $Johnson & Johnson (JNJ.US)$ move to me and I don't buy it. Not from Roche.

$Sophia Genetics (SOPH.US)$ $AstraZeneca (AZN.US)$
Global Healthcare Revolution: Elite Hospitals Rush to Implement This Game-Changing Cancer Test

$AstraZeneca (AZN.US)$
Breakthrough in Bladder Cancer Treatment: AstraZeneca's IMFINZI Slashes Disease Progression Risk by 42%

$AstraZeneca (AZN.US)$
Groundbreaking Digital Adventure Helps Kids Master Their Rare Kidney Disease Journey

$AstraZeneca (AZN.US)$ $Compugen (CGEN.US)$
Major Breakthrough: AstraZeneca's New Weapon Against Early-Stage Lung Cancer Enters Final Testing

$LumiraDx (LMDXF.US)$ @BadPaint revisiting your Bill Gates post about him not selling his shares. It was announced while Lumiradx was on expert market I believe. Now I will say this, all the institutions that sold could have sold prior to expert market and bought back in during expert through an offshore entity. Zwanziger Ventures LLC perhaps? Can you dig more into Senvest for us?
Off topic here a bit however I found this intriguing that Cobas was introduced in '94 however Roche only started divi...

$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...